Published in Proc Natl Acad Sci U S A on February 01, 1994
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med (2004) 2.89
Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol (2000) 2.04
CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med (1996) 1.62
Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol (2007) 1.62
A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med (1997) 1.59
Defect in IgV gene somatic hypermutation in common variable immuno-deficiency syndrome. Proc Natl Acad Sci U S A (1998) 1.51
B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol (2010) 1.39
Human CD14hi monocytes and myeloid dendritic cells provide a cell contact-dependent costimulatory signal for early CD40 ligand expression. Blood (2010) 1.39
Diminished expression of CD40 ligand by activated neonatal T cells. J Clin Invest (1995) 1.39
Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol (2008) 1.24
Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodeficiency (CVID). Clin Exp Immunol (2002) 1.19
Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation. J Allergy Clin Immunol (2007) 1.17
International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract (2015) 1.11
B-cell targeted therapeutics in clinical development. Arthritis Res Ther (2013) 1.09
Hyper IgM syndrome associated with defective CD40-mediated B cell activation. J Clin Invest (1994) 1.05
Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol (2011) 1.03
X-linked immunodeficiency with hyper-IgM (XHIM). Clin Exp Immunol (2000) 1.02
Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol (2005) 1.01
A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome. J Clin Invest (1996) 1.00
Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol (2009) 0.96
Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients. Clin Exp Immunol (1995) 0.95
Gene expression analysis of peripheral T cells in a subgroup of common variable immunodeficiency shows predominance of CCR7(-) effector-memory T cells. Clin Exp Immunol (2004) 0.93
Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients. Clin Exp Immunol (1997) 0.92
A decreased frequency of regulatory T cells in patients with common variable immunodeficiency. PLoS One (2009) 0.91
Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation. J Allergy Clin Immunol (2011) 0.90
Characterization of nine novel mutations in the CD40 ligand gene in patients with X-linked hyper IgM syndrome of various ancestry. Am J Hum Genet (1995) 0.90
Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge. J Clin Immunol (2014) 0.86
Three novel mutations reflect the variety of defects causing phenotypically diverse X-linked hyper-IgM syndrome. Clin Exp Immunol (2003) 0.81
Defective surface expression of attractin on T cells in patients with common variable immunodeficiency (CVID). Clin Exp Immunol (2001) 0.79
Community-acquired poliovirus infection in children with primary immunodeficiencies in Tunisia. J Clin Microbiol (2003) 0.79
Autoimmune manifestations in common variable immunodeficiency. Clin Rheumatol (2004) 0.78
Serum soluble CD23 in patients with hypogammaglobulinaemia. Clin Exp Immunol (1994) 0.78
T-cell response to viral antigens in adults and children with common variable immunodeficiency and specific antibody deficiency. Clin Exp Immunol (2010) 0.78
Common variable immunodeficiency: etiological and treatment issues. Int Arch Allergy Immunol (2009) 0.77
Characterization of Herpesvirus saimiri-transformed T lymphocytes from common variable immunodeficiency patients. Clin Exp Immunol (2002) 0.77
Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help. Oncotarget (2015) 0.76
Common variable immunodeficiency (CVID) and MxA-protein expression in blood leucocytes. Clin Exp Immunol (1995) 0.76
A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID). Clin Exp Immunol (1997) 0.76
Autologous human cytomegalovirus-specific cytotoxic T cells as rescue therapy for ulcerative enteritis in primary immunodeficiency. J Clin Immunol (2014) 0.76
Identification of a subset of common variable immunodeficiency patients with impaired B-cell protein tyrosine phosphorylation. Clin Diagn Lab Immunol (1999) 0.76
Association of HLA-DRB1, DQA1 and DQB1 Alleles and Haplotypes with Common Variable Immunodeficiency in Iranian Patients. Avicenna J Med Biotechnol (2012) 0.75
Chronic Giardiasis in a Case of Common Variable Immunodeficiency (CVID): A Case Report. J Clin Diagn Res (2016) 0.75
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A (1992) 6.37
CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science (1993) 5.04
Molecular and biological characterization of a murine ligand for CD40. Nature (1992) 4.83
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature (1993) 4.39
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell (1993) 4.30
CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature (1993) 4.11
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 3.68
CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med (1990) 3.67
Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex. Nature (1985) 3.34
Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med (1991) 3.04
Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med (1992) 2.86
Quantitative measurements of T- and B-cell function in "variable" primary hypogammaglobulinaemia: evidence for a consistent B-cell defect. Clin Exp Immunol (1977) 2.62
Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol (1992) 2.54
Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc Natl Acad Sci U S A (1987) 2.53
Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol (1989) 2.40
CD40 stimulation provides an IFN-gamma-independent and IL-4-dependent differentiation signal directly to human B cells for IgE production. J Immunol (1991) 2.28
Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A (1993) 2.17
Suppression of B-cell differentiation by leukocytes from hypogammaglobulinemic patients. J Clin Invest (1976) 2.15
Circulating B-cells in patients with immunodeficiency. Am J Pathol (1972) 2.07
Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J Immunol (1991) 2.07
CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today (1992) 1.93
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest (1971) 1.76
The chromosomal location of T-cell receptor genes and a T cell rearranging gene: possible correlation with specific translocations in human T cell leukaemia. EMBO J (1985) 1.64
Regulation of human B-cell activation and adhesion. Annu Rev Immunol (1991) 1.64
Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol (1992) 1.62
Three distinct stages of B-cell defects in common varied immunodeficiency. Proc Natl Acad Sci U S A (1982) 1.60
Cellular abnormalities in common variable immunodeficiency. Immunodefic Rev (1990) 1.56
Abnormalities of T cell maturation and regulation in human beings with immunodeficiency disorders. J Clin Invest (1981) 1.50
Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency. J Immunol (1990) 1.46
Immunoglobulins on the surface of lymphocytes in fifty patients with primary immunodeficiency diseases. Clin Immunol Immunopathol (1973) 1.46
Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol (1984) 1.44
Synergistic interaction between interleukin 4 and anti-Bp50 (CDw40) revealed in a novel B cell restimulation assay. Eur J Immunol (1987) 1.41
Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J Exp Med (1992) 1.38
B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med (1993) 1.35
Polyclonal immunoglobulin secretion in patients with common variable immunodeficiency using monoclonal B cell differentiation factors. J Clin Invest (1984) 1.23
Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin. J Clin Invest (1993) 1.07
Mapping of the X-linked form of hyper-IgM syndrome (HIGM1) to Xq26 by close linkage to HPRT. Genomics (1992) 1.02
Human T cell activation. IV. T cell activation and proliferation via the early activation antigen EA 1. J Exp Med (1989) 0.95
Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J Biol Chem (1992) 0.92
Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev (1979) 16.45
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27
Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A (1987) 12.15
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science (1989) 7.78
Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med (1981) 6.82
T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J Exp Med (1980) 6.62
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 6.61
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A (1990) 6.19
The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol (1993) 5.65
Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. Proc Natl Acad Sci U S A (1985) 5.50
An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol (1986) 5.14
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A (1989) 5.07
Visualization of specific B and T lymphocyte interactions in the lymph node. Science (1998) 5.04
Role of the CD28 receptor in T-cell activation. Immunol Today (1990) 4.89
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol (1987) 4.76
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science (1992) 4.53
Mice deficient for the CD40 ligand. Immunity (1994) 4.45
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell (1993) 4.30
Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell (1994) 4.04
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol (1988) 3.88
Minor Xp21 chromosome deletion in a male associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and McLeod syndrome. Am J Hum Genet (1985) 3.83
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 3.77
Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science (1990) 3.74
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 3.73
Definition of a common leukocyte cell-surface antigen (Lp95-150) associated with diverse cell-mediated immune functions. J Immunol (1983) 3.70
Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci U S A (1990) 3.69
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 3.68
Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol (1996) 3.56
The role of neutrophil membrane glycoprotein GP-150 in neutrophil adherence to endothelium in vitro. Blood (1985) 3.53
Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol (1990) 3.51
CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med (2001) 3.51
How B and T cells talk to each other. Nature (1994) 3.37
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 3.34
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science (1993) 3.30
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J (1991) 3.20
Partial V(D)J recombination activity leads to Omenn syndrome. Cell (1998) 3.18
Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol (1986) 3.08
Identification of nocardia species by restriction endonuclease analysis of an amplified portion of the 16S rRNA gene. J Clin Microbiol (2000) 3.05
Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature (1992) 2.97
gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med (1994) 2.87
A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science (1995) 2.84
CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol (1990) 2.84
In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med (1993) 2.72
Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med (1993) 2.71
Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet (1999) 2.63
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc Natl Acad Sci U S A (1987) 2.53
The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol (1993) 2.53
Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol (1985) 2.46
Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med (1992) 2.42
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med (1996) 2.39
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1996) 2.38
CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol (1995) 2.38
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med (1994) 2.37
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J (1998) 2.36
The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today (1994) 2.36
Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol (1992) 2.36
Immune response after splenectomy. Lancet (1978) 2.31
The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells. Cell (1991) 2.24
CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood (1990) 2.21
Loss of CD45R (Lp220) represents a post-thymic T cell differentiation event. J Immunol (1988) 2.20
A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation. J Immunol (1981) 2.20
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17